Liposcience, Inc.

Lipscience, Inc.

Beth Israel Deaconess Medical Center, Inc.

Elias J Jeyarajah

James D Otvos

Steven P Matyus

Dennis W Bennett

David R Morgan

Justyna E Wolak-Dinsmore

Thomas M O'Connell

Bruce D Silberman

Donald R Deuel

Stephen Markham

Stanley Leon Hazen

Irina Y Shalaurova

Margery A Connelly

Stanley L Hazan

John Contois

Lili Duan

Qun Zhou

Steve Markham

Russell Reeve

Nezam Hassan Afdhal

Michael Curry

Yury Popov

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide ('TMAO'). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 &#x3bc;M or urine with a normal biologic range of between about 0-1000 &#x3bc;M.

NMR quantification of TMAO

The clinical analyzers automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites.

NMR analyzers for clinical evaluation of biosamples

NMR analyzers and associated methods, circuits and computer program products that allow NMR operation in fluctuating ambient temperature environments of at least +/&#x2212;5 degrees F. in a relatively large operating temperature range, typically between about 60-85 degrees F.) with the ability to still generate accurate quantitative measurements using an electronically applied temperature sensitivity adjustment based on an a priori model of temperature sensitivity and a detected temperature proximate the NMR signal acquisition (e.g., scan). The clinical NMR analyzers can be remotely accessed to evaluate linearity and temperature compensation adjustments.

Quantitative NMR clinical analyzers with automatic NMR temperature sensitivity compensation that accommodate large ambient operational temperature ranges

Methods, computer program products, NMR assays and automated/semi-automated systems measure concentrations of ionized calcium and/or magnesium or other metabolites in clinical biosamples using NMR data obtained from an NMR spectrometer, such as a clinical NMR Analyzer.

NMR measurement of clinically relevant ionized biosample constituents such as ionized calcium and/or magnesium

Methods, computer program products and apparatus automate clinical NMR in vitro diagnostic analyzers. The clinical analyzer can automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites; and at least one remote control system in communication with one or a plurality of clinical NMR analyzers, the at least one remote system configured to monitor selected local operating parameters associated with a respective clinical NMR analyzer.

NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples

Methods, systems and computer programs are configured to determine the presence of and/or a measurement for a plurality of constituents in a composite signal with closely correlated chemical constituents having overlapping signal lineshapes extending about a spectrum of interest obtained from a target sample undergoing analysis.

Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals

A method of screening a subject for the presence of lipoprotein X includes the steps of: producing a measured lipid signal lineshape of an NMR spectrum of a blood plasma or serum sample obtained from a subject; generating a calculated lineshape for the sample, the calculated lineshape being based on derived concentrations of lipoprotein components potentially present in the sample, the derived concentration of each of the lipoprotein components being the function of a reference spectrum for that component and a calculated reference coefficient, wherein one of the lipoprotein components for which a concentration is calculated is lipoprotein X; and determining the degree of correlation between the calculated lineshape of the sample and the measured lineshape spectrum of the sample. This method can enable the practitioner, during a routine and easily-conducted cholesterol screening, to identify the presence of LP-X in a subject and begin diagnosis and treatment for conditions associated with LP-X (such as liver disease or LCAT deficiency).

Method of determining presence and concentration of lipoprotein X in blood plasma and serum

Growing community of inventors

Raleigh, NC, United States of America

Elias J Jeyarajah